Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: INPP5D

Gene summary for INPP5D

Gene summary.

Gene information	Species	Human
	Gene symbol	INPP5D
	Gene ID	3635
	Gene name	inositol polyphosphate-5-phosphatase D
	Gene Alias	SHIP
	Cytomap	2q37.1
	Gene Type	protein-coding
	GO ID	GO:0001775
	UniProtAcc	Q92835

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
3635	INPP5D	HTA11_3410_2000001011	Human	Colorectum	AD	2.77e-23	3.86e-01	0.0155
3635	INPP5D	HTA11_2487_2000001011	Human	Colorectum	SER	1.03e-06	2.53e-01	-0.1808
3635	INPP5D	HTA11_2951_2000001011	Human	Colorectum	AD	4.03e-07	5.92e-01	0.0216
3635	INPP5D	HTA11_1938_2000001011	Human	Colorectum	AD	1.24e-26	6.62e-01	-0.0811
3635	INPP5D	HTA11_78_2000001011	Human	Colorectum	AD	7.84e-13	3.98e-01	-0.1088
3635	INPP5D	HTA11_3361_2000001011	Human	Colorectum	AD	3.75e-08	1.97e-01	-0.1207
3635	INPP5D	HTA11_83_2000001011	Human	Colorectum	SER	4.77e-05	3.69e-01	-0.1526
3635	INPP5D	HTA11_696_2000001011	Human	Colorectum	AD	2.81e-02	1.05e-01	-0.1464
3635	INPP5D	HTA11_866_2000001011	Human	Colorectum	AD	1.70e-12	3.77e-01	-0.1001
3635	INPP5D	HTA11_1391_2000001011	Human	Colorectum	AD	2.72e-21	6.10e-01	-0.059
3635	INPP5D	HTA11_866_3004761011	Human	Colorectum	AD	1.69e-20	4.99e-01	0.096
3635	INPP5D	HTA11_9408_2000001011	Human	Colorectum	AD	6.81e-06	3.67e-01	0.0451
3635	INPP5D	HTA11_10711_2000001011	Human	Colorectum	AD	4.40e-20	5.58e-01	0.0338
3635	INPP5D	HTA11_7696_3000711011	Human	Colorectum	AD	1.08e-27	7.17e-01	0.0674
3635	INPP5D	HTA11_6818_2000001011	Human	Colorectum	AD	5.93e-06	3.72e-01	0.0112
3635	INPP5D	HTA11_6818_2000001021	Human	Colorectum	AD	5.74e-17	3.70e-01	0.0588
3635	INPP5D	HTA11_99999970781_79442	Human	Colorectum	MSS	6.68e-24	4.92e-01	0.294
3635	INPP5D	HTA11_99999965062_69753	Human	Colorectum	MSI-H	8.64e-08	1.10e+00	0.3487
3635	INPP5D	HTA11_99999965104_69814	Human	Colorectum	MSS	2.78e-12	3.99e-01	0.281
3635	INPP5D	HTA11_99999971662_82457	Human	Colorectum	MSS	8.98e-27	7.16e-01	0.3859

Page: 1 2

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Colorectum (GSE201348)		FAP: Familial adenomatous polyposis
		CRC: Colorectal cancer
Colorectum (HTA11)		AD: Adenomas
		SER: Sessile serrated lesions
		MSI-H: Microsatellite-high colorectal cancer
		MSS: Microsatellite stable colorectal cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:0034101	Colorectum	AD	erythrocyte homeostasis	51/3918	129/18723	1.07e-06	3.59e-05	51
GO:0030099	Colorectum	AD	myeloid cell differentiation	119/3918	381/18723	1.24e-06	4.01e-05	119
GO:0002262	Colorectum	AD	myeloid cell homeostasis	57/3918	157/18723	6.17e-06	1.56e-04	57
GO:0048872	Colorectum	AD	homeostasis of number of cells	87/3918	272/18723	1.16e-05	2.61e-04	87
GO:0016311	Colorectum	AD	dephosphorylation	123/3918	417/18723	1.84e-05	3.82e-04	123
GO:0030218	Colorectum	AD	erythrocyte differentiation	45/3918	120/18723	2.22e-05	4.39e-04	45
GO:0060249	Colorectum	AD	anatomical structure homeostasis	94/3918	314/18723	9.37e-05	1.42e-03	94
GO:0030258	Colorectum	AD	lipid modification	67/3918	212/18723	1.66e-04	2.27e-03	67
GO:0001894	Colorectum	AD	tissue homeostasis	81/3918	268/18723	1.96e-04	2.62e-03	81
GO:0007568	Colorectum	AD	aging	98/3918	339/18723	2.77e-04	3.39e-03	98
GO:0030224	Colorectum	AD	monocyte differentiation	17/3918	36/18723	3.79e-04	4.36e-03	17
GO:0045646	Colorectum	AD	regulation of erythrocyte differentiation	20/3918	47/18723	6.54e-04	6.75e-03	20
GO:1903706	Colorectum	AD	regulation of hemopoiesis	99/3918	367/18723	3.08e-03	2.28e-02	99
GO:0045637	Colorectum	AD	regulation of myeloid cell differentiation	61/3918	210/18723	3.17e-03	2.35e-02	61
GO:0002573	Colorectum	AD	myeloid leukocyte differentiation	60/3918	208/18723	4.03e-03	2.81e-02	60
GO:0006650	Colorectum	AD	glycerophospholipid metabolic process	83/3918	306/18723	5.40e-03	3.55e-02	83
GO:0006644	Colorectum	AD	phospholipid metabolic process	101/3918	383/18723	5.80e-03	3.67e-02	101
GO:0045017	Colorectum	AD	glycerolipid biosynthetic process	69/3918	252/18723	8.33e-03	4.88e-02	69
GO:00341011	Colorectum	SER	erythrocyte homeostasis	39/2897	129/18723	1.70e-05	5.11e-04	39
GO:00022621	Colorectum	SER	myeloid cell homeostasis	44/2897	157/18723	4.09e-05	1.03e-03	44

Page: 1 2 3 4 5

Enriched KEGG pathways.

Pathway ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	qvalue	Count
hsa04666	Colorectum	AD	Fc gamma R-mediated phagocytosis	46/2092	97/8465	9.10e-07	1.22e-05	7.77e-06	46
hsa046661	Colorectum	AD	Fc gamma R-mediated phagocytosis	46/2092	97/8465	9.10e-07	1.22e-05	7.77e-06	46
hsa046662	Colorectum	SER	Fc gamma R-mediated phagocytosis	39/1580	97/8465	5.84e-07	9.70e-06	7.04e-06	39
hsa046663	Colorectum	SER	Fc gamma R-mediated phagocytosis	39/1580	97/8465	5.84e-07	9.70e-06	7.04e-06	39
hsa046664	Colorectum	MSS	Fc gamma R-mediated phagocytosis	45/1875	97/8465	9.30e-08	1.56e-06	9.55e-07	45
hsa046665	Colorectum	MSS	Fc gamma R-mediated phagocytosis	45/1875	97/8465	9.30e-08	1.56e-06	9.55e-07	45
hsa046666	Colorectum	FAP	Fc gamma R-mediated phagocytosis	35/1404	97/8465	2.46e-06	4.28e-05	2.60e-05	35
hsa046667	Colorectum	FAP	Fc gamma R-mediated phagocytosis	35/1404	97/8465	2.46e-06	4.28e-05	2.60e-05	35
hsa046668	Colorectum	CRC	Fc gamma R-mediated phagocytosis	27/1091	97/8465	6.24e-05	1.12e-03	7.57e-04	27
hsa046669	Colorectum	CRC	Fc gamma R-mediated phagocytosis	27/1091	97/8465	6.24e-05	1.12e-03	7.57e-04	27

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

INPP5D

SNV

Missense_Mutation

novel

c.345N>A

p.Asp115Glu

p.D115E

Q92835

protein_coding

tolerated(0.58)

benign(0.001)

TCGA-AO-A03V-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

fluorouracil

INPP5D

SNV

Missense_Mutation

rs758989076

c.3170N>T

p.Ser1057Leu

p.S1057L

Q92835

protein_coding

deleterious_low_confidence(0.05)

benign(0.003)

TCGA-AQ-A7U7-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Targeted Molecular therapy

rituximab

INPP5D

SNV

Missense_Mutation

c.1606N>A

p.Gly536Arg

p.G536R

Q92835

protein_coding

deleterious(0)

probably_damaging(0.999)

TCGA-B6-A0RS-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

INPP5D

SNV

Missense_Mutation

c.2344N>A

p.Glu782Lys

p.E782K

Q92835

protein_coding

tolerated(0.79)

benign(0.109)

TCGA-BH-A18F-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

taxotere

INPP5D

SNV

Missense_Mutation

rs781285468

c.1934N>A

p.Arg645His

p.R645H

Q92835

protein_coding

deleterious(0)

probably_damaging(0.999)

TCGA-D8-A1JK-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

INPP5D

SNV

Missense_Mutation

novel

c.1730A>G

p.His577Arg

p.H577R

Q92835

protein_coding

tolerated(0.84)

benign(0.286)

TCGA-2W-A8YY-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

INPP5D

SNV

Missense_Mutation

c.1982C>T

p.Ala661Val

p.A661V

Q92835

protein_coding

deleterious(0.01)

probably_damaging(0.989)

TCGA-2W-A8YY-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

INPP5D

SNV

Missense_Mutation

rs769891270

c.3130C>T

p.Arg1044Trp

p.R1044W

Q92835

protein_coding

deleterious(0)

possibly_damaging(0.865)

TCGA-2W-A8YY-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

INPP5D

SNV

Missense_Mutation

c.3233N>C

p.Val1078Ala

p.V1078A

Q92835

protein_coding

tolerated_low_confidence(0.45)

benign(0)

TCGA-C5-A7UH-01

Cervix

cervical & endocervical cancer

Female

<65

III/IV

Chemotherapy

cisplatin

INPP5D

SNV

Missense_Mutation

rs201032928

c.3131G>A

p.Arg1044Gln

p.R1044Q

Q92835

protein_coding

deleterious(0.03)

benign(0.267)

TCGA-C5-A7X3-01

Cervix

cervical & endocervical cancer

Female

>=65

III/IV

Chemotherapy

cisplatin

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID	Symbol	Category	Interaction Types	Drug Claim Name	Drug Name	PMIDs
3635	INPP5D	DRUGGABLE GENOME, KINASE, ENZYME, CLINICALLY ACTIONABLE	activator	315661324	ROSIPTOR
3635	INPP5D	DRUGGABLE GENOME, KINASE, ENZYME, CLINICALLY ACTIONABLE		TURNAGAINOLIDE B	TURNAGAINOLIDE B	21539394
3635	INPP5D	DRUGGABLE GENOME, KINASE, ENZYME, CLINICALLY ACTIONABLE	inhibitor	336446950
3635	INPP5D	DRUGGABLE GENOME, KINASE, ENZYME, CLINICALLY ACTIONABLE		AQX-1125	ROSIPTOR

Page: 1